The Conference Call on Q3 2024 financial results takes place on November 5, 2024
To comply with article 19 of the Regulation (EU) No 596/2014 (Market Abuse Regulation), members of our Management and Supervisory Board as well as other persons discharching managerial responsibilities and all person closely associated with the aforementioned persons shall notify the Company of each transaction with shares of Fresenius Medical Care and additional related financial instruments conducted on their own account if the transaction volume reaches a total amount of EUR 20,000 within a single year.